## REMARKS

The Official Action of October 31 was a requirement for restriction. In that Action, the Examiner required three different elections, one to a specie selected from the group consisting of polydocanol, sodium tetradecyl sulfate, and hypertonic glucostated or glucosaline solution. Further, a requirement was required as to one of the species of chromate glycerol, ethanolamine oleate, sodium morrhuate, and any iodate solution. Still further, an election was required as between phlebology, esophageal varices, proctology, and angiology.

The claims were modified because, in actuality, the first two requirements for restriction should be grouped together. As will be seen from page 3, lines 3 through 8 of the filed specification, all of the materials in Claims 2 through 8 are sclerosing agents and that is made clear by the amendments to Claims 5 through 8.

It is applicant's belief that to fully protect the invention, each of the claims should remain in a single application. However, in order to be fully responsive to the requirement for restriction, applicant selects for further prosecution sodium tetradecyl sulfate as the single sclerosing agent and angiology as the single use. Thus, applicant has elected for further prosecution Claims 3 and 20, along with generic Claims 1 and 18.

Reconsideration of the requirement for restriction and allowance of each of the presently pending claims are respectfully requested.

Respectfully submitted,

Martin E. Goldstein, Esq.

Reg. No. 20,869

Attorney for Applicant(s)

DARBY & DARBY, P.C. 805 Third Avenue New York, New York 10022-7513 (212) 527-7700